Work

CRISPR-directed exon skipping; friend or foe (opportunity or warning sign)?

Year: 2025

Type: article

Abstract: Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.

Source: Molecular Therapy — Nucleic Acids

DOI: 10.1016/j.omtn.2025.102539

Authors: Kelly H. Banas, Eric B. Kmiec

Institution: Christiana Care Health System

Language: English

Topic: CRISPR and Genetic Engineering

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

Open Access status: gold

Estimated APC paid: $3,900

Funders: National Institutes of Health, National Institute of General Medical Sciences